EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, GLUE: Monte Rosa Therapeutics Inc

13 Nov 25 15:59
LAST:

14.33

CHANGE:
 0.16		OPEN:
13.99		HIGH:
14.35		ASK:
0.00		VOLUME:
624.4K
CHG(%):
1.13		PREV:
14.16		LOW:
13.71		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
13 Nov 2513.9914.3513.7314.321.02M
12 Nov 2514.3114.3813.8914.161.02M
11 Nov 2513.5314.4012.7414.321.69M
10 Nov 2512.5214.1112.4014.061.23M
07 Nov 2512.7313.3711.9012.31730.4K
06 Nov 2512.4013.5912.0513.011.55M
05 Nov 2511.9312.3911.6912.31582.8K
04 Nov 2511.6512.3111.5012.00630.1K
03 Nov 2512.7412.9911.8012.07925.2K
31 Oct 2513.0113.2212.5212.851.15M

COMPANY PROFILE

Name:Monte Rosa Therapeutics Inc
About:Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1b and the NLRP3 inflammasome. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd. to discover and develop MGDs against targets in cancer and neurological diseases. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Sector:Healthcare
Industry:Biotechnology
Address:321 Harrison Avenue, Boston, MA, United States, 02118
Website:https://www.monterosatx.com
CUSIP:61225M102
CIK:0001826457
ISIN:US61225M1027
FIGI:BBG00X2VGZQ3

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:30.74 
Forward P/E:-7.99 
PEG Ratio:-0.57 
Price to Sales:4.16 
Price to Book:2.76 
Profit Margin:0.14 
Operating Margin:-0.67 
Return on Assets:0.03 
Return on Equity:0.10 
EPS Ratio:0.39 
Revenue:177.99M 
EBITDA:23.3M 
Shares:61.76M 
Market Cap:885.01M 

TECHNICAL INDICATORS

MA5:13.833.6%
MA10:13.149.0%
MA20:12.1018.4%
MA50:9.1856.1%
MA100:7.06102.9%
MA200:6.10135.1%
STO9:96.67 
STO14:96.67 
RSI14:72.98 
MTM14:2.00
ROC14:0.16 
ATR:1.06 
Week High:14.400.5%
Week Low:11.9020.4%
Month High:14.400.5%
Month Low:8.94135.1%
Year High:14.400.5%
Year Low:3.50309.4%